Denali Therapeutics (DNLI) Receivables - Net: 2018-2025
Historic Receivables - Net for Denali Therapeutics (DNLI) over the last 5 years, with Sep 2025 value amounting to $1.9 million.
- Denali Therapeutics' Receivables - Net rose 35.71% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 35.71%. This contributed to the annual value of $1.5 million for FY2024, which is 56.14% down from last year.
- According to the latest figures from Q3 2025, Denali Therapeutics' Receivables - Net is $1.9 million, which was up 35.71% from $1.4 million recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Receivables - Net peaked at $15.2 million during Q2 2021, and registered a low of $1.4 million during Q2 2024.
- Its 3-year average for Receivables - Net is $2.1 million, with a median of $1.9 million in 2025.
- Its Receivables - Net has fluctuated over the past 5 years, first skyrocketed by 4,972.67% in 2021, then slumped by 63.15% in 2023.
- Quarterly analysis of 5 years shows Denali Therapeutics' Receivables - Net stood at $15.2 million in 2021, then reached $9.3 million in 2022, then tumbled by 63.15% to $3.4 million in 2023, then crashed by 56.14% to $1.5 million in 2024, then surged by 35.71% to $1.9 million in 2025.
- Its Receivables - Net was $1.9 million in Q3 2025, compared to $1.4 million in Q2 2025 and $1.7 million in Q1 2025.